Assessment of Patient Satisfaction With Appearance, Psychological Well-Being, and Aging Appraisal After Upper Blepharoplasty: A Multicenter Prospective Cohort Study

Abstract Background To determine the success of an upper blepharoplasty, a popular cosmetic procedure, it is essential to measure outcomes from the patient perspective, these often outweigh objective outcomes. Objectives This study aimed to assess patient-reported satisfaction with facial appearance, psychological well-being, and aging appraisal after upper blepharoplasty with validated questionnaires. Methods This prospective cohort study included upper blepharoplasty patients from eight outpatient clinics. Patient-reported satisfaction was assessed using the FACE-Q at intake, six and twelve months postoperative. Results 2134 patients were included. High satisfaction with outcome and decision to undergo treatment were measured six months postoperative. Large improvements in FACE-Q scores (range, 0 - 100) between intake and six months postoperative were seen for satisfaction with appearance (mean, effect size; eyes +48, 2.6; upper eyelids +48, 3.1; facial appearance overall +26, 1.4), psychological well-being (+11, 0.56) and aging appraisal (+22, 1.0). Patients reported to appear 3.3 years younger (SD, ±5.2) postblepharoplasty. No clinically relevant changes were seen between six and twelve months. Additionally, improvements in appearance were not dependent on their intake scores, whereas improvements in psychological well-being and aging appraisal were smaller in patients with higher intake scores. Satisfaction with treatment outcome was strongly correlated with appearance satisfaction but not with aging appraisal. Conclusions Significant improvements in patient satisfaction regarding appearance, psychological well-being, and aging appraisal can be seen 6 months after blepharoplasty, and outcomes remain stable up to 12 months postoperative. These data may be used to inform patients and clinicians and improve the overall quality of care.

Download Full-text

Significantly Increased Patient Satisfaction Following Liquid Formulation AbobotulinumtoxinA Treatment in Glabellar Lines: FACE-Q Outcomes From a Phase 3 Clinical Trial

Aesthetic Surgery Journal ◽

10.1093/asj/sjz248 ◽

2019 ◽

Vol 40 (9) ◽

pp. 1000-1008 ◽

Cited By ~ 2

Author(s):

Benjamin Ascher ◽

Berthold Rzany ◽

Philippe Kestemont ◽

Said Hilton ◽

Marc Heckmann ◽

...

Keyword(s):

Patient Satisfaction ◽

Least Squares ◽

Controlled Trial ◽

Well Being ◽

Facial Appearance ◽

Liquid Formulation ◽

Phase 3 ◽

Level Of Evidence ◽

Psychological Well Being ◽

Patient Reported

Abstract Background The FACE-Q patient-reported outcome assesses patient experiences/outcomes with aesthetic facial procedure. A recent trial of abobotulinumtoxinA (ASI, liquid formulation) was the first to our knowledge to assess satisfaction with FACE-Q after glabellar line (GL) injection. Objectives The authors sought to evaluate patient satisfaction with ASI for GL treatment employing 3 FACE-Q scales: facial appearance, psychological well-being, and aging appearance. Methods This was a Phase 3, randomized, double-blind, placebo-controlled trial (NCT02353871) of ASI 50 units in adults with moderate-to-severe GL with 6-month follow-up. Results Significantly greater least squares mean changes from baseline were associated with ASI treatment (N = 125) vs placebo (N = 59) for satisfaction with facial appearance at all visits until day 148 (5 months; P < 0.0001-0.0037), psychological well-being at all visits (P < 0.0001-0.0279), and aging appearance at all visits except day 148 (P < 0.0001-0.0409). Significant differences (ASI vs placebo) were observed at all visits for individual items: “how rested your face looks” (P < 0.0001-0.0415), “I feel okay about myself” (P = 0.0011-0.0399), and “I feel attractive” (P < 0.0001-0.0102). Maximal least squares mean (standard error) changes in aging appearance score were −1.4 (0.3; ASI) and −0.3 (0.4; placebo). Investigators’ live assessment of GL at maximum frown significantly correlated with improvements in FACE-Q facial appearance and psychological scales (all patients: r = −0.41 and r = −0.36 [both P < 0.0001], respectively). Conclusions Significant improvements in patient satisfaction with aging, facial appearance, and, importantly, psychological well-being were demonstrated with ASI employing FACE-Q scales up to 5 to 6 months post-injection. Results support a long duration of efficacy with ASI and use of FACE-Q in future trials and clinical practice. Level of Evidence: 1

Download Full-text

Sociodemographic, personal, and disease-related determinants of referral to patient-reported outcome-based follow-up of remote outpatients: a prospective cohort study

Quality of Life Research ◽

10.1007/s11136-019-02407-2 ◽

2020 ◽

Vol 29 (5) ◽

pp. 1335-1347 ◽

Cited By ~ 1

Author(s):

Liv Marit Valen Schougaard ◽

Annette de Thurah ◽

Jakob Christensen ◽

Kirsten Lomborg ◽

Helle Terkildsen Maindal ◽

...

Keyword(s):

Cohort Study ◽

Health Literacy ◽

Prospective Cohort Study ◽

Self Efficacy ◽

Prospective Cohort ◽

General Health ◽

Patient Activation ◽

Well Being ◽

Patient Reported

Abstract Purpose We examined the association between sociodemographic, personal, and disease-related determinants and referral to a new model of health care that uses patient-reported outcomes (PRO) measures for remote outpatient follow-up (PRO-based follow-up). Methods We conducted a prospective cohort study among outpatients with epilepsy at the Department of Neurology at Aarhus University Hospital, Denmark. Included were all persons aged ≥ 15 years visiting the department for the first time during the period from May 2016 to May 2018. Patients received a questionnaire containing questions about health literacy, self-efficacy, patient activation, well-being, and general health. We also collected data regarding sociodemographic status, labour market affiliation, and co-morbidity from nationwide registers. Associations were analysed as time-to-event using the pseudo-value approach. Missing data were handled using multiple imputations. Results A total of 802 eligible patients were included in the register-based analyses and 411 patients (51%) responded to the questionnaire. The results based on data from registers indicated that patients were less likely to be referred to PRO-based follow-up if they lived alone, had low education or household income, received temporary or permanent social benefits, or if they had a psychiatric diagnosis. The results based on data from the questionnaire indicated that patients were less likely to be referred to PRO-based follow-up if they reported low levels of health literacy, self-efficacy, patient activation, well-being, or general health. Conclusion Both self-reported and register-based analyses indicated that socioeconomically advantaged patients were referred more often to PRO-based follow-up than socioeconomically disadvantaged patients.

Download Full-text

Patient-reported Quality of Life following Stereotactic Body Radiation Therapy for Primary Kidney Cancer – Results from a Prospective Cohort Study

Clinical Oncology ◽

10.1016/j.clon.2021.03.002 ◽

2021 ◽

Author(s):

A. Swaminath ◽

P. Cheung ◽

R.M. Glicksman ◽

E.K. Donovan ◽

M. Niglas ◽

...

Keyword(s):

Quality Of Life ◽

Radiation Therapy ◽

Cohort Study ◽

Kidney Cancer ◽

Prospective Cohort Study ◽

Prospective Cohort ◽

Stereotactic Body Radiation Therapy ◽

Stereotactic Body Radiation ◽

Patient Reported

Download Full-text

Shoulder function after constraint-induced movement therapy assessed with 3D kinematics and clinical and patient reported outcomes: a prospective cohort study

Journal of Electromyography and Kinesiology ◽

10.1016/j.jelekin.2021.102547 ◽

2021 ◽

pp. 102547

Author(s):

Gunhild Mo Hansen ◽

Susanne Wulff Svendsen ◽

Asger Roer Pedersen ◽

Uwe Gustav Kersting ◽

Hanne Pallesen ◽

...

Keyword(s):

Cohort Study ◽

Prospective Cohort Study ◽

Prospective Cohort ◽

Patient Reported Outcomes ◽

Movement Therapy ◽

Shoulder Function ◽

3D Kinematics ◽

Constraint Induced Movement Therapy ◽

Patient Reported

Download Full-text

The INTREST registry: protocol of a multicenter prospective cohort study of predictors of women’s response to integrative breast cancer treatment

BMC Cancer ◽

10.1186/s12885-021-08468-2 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Heidemarie Haller ◽

Petra Voiß ◽

Holger Cramer ◽

Anna Paul ◽

Mattea Reinisch ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Cohort Study ◽

Cancer Treatment ◽

Prospective Cohort Study ◽

Cancer Care ◽

Prospective Cohort ◽

Breast Cancer Treatment ◽

Cancer Data ◽

Patient Reported

Abstract Background Cancer registries usually assess data of conventional treatments and/or patient survival. Beyond that, little is known about the influence of other predictors of treatment response related to the use of complementary therapies (CM) and lifestyle factors affecting patients’ quality and quantity of life. Methods INTREST is a prospective cohort study collecting register data at multiple German certified cancer centers, which provide individualized, integrative, in- and outpatient breast cancer care. Patient-reported outcomes and clinical cancer data of anticipated N = 715 women with pTNM stage I-III breast cancer are collected using standardized case report forms at the time of diagnosis, after completing neo−/adjuvant chemotherapy, after completing adjuvant therapy (with the exception of endocrine therapy) as well as 1, 2, 5, and 10 years after baseline. Endpoints for multivariable prediction models are quality of life, fatigue, treatment adherence, and progression-based outcomes/survival. Predictors include the study center, sociodemographic characteristics, histologic cancer and comorbidity data, performance status, stress perception, depression, anxiety, sleep quality, spirituality, social support, physical activity, diet behavior, type of conventional treatments, use of and belief in CM treatments, and participation in a clinical trial. Safety is recorded following the Common Terminology Criteria for Adverse Events. Discussion This trial is currently recruiting participants. Future analyses will allow to identify predictors of short- and long-term response to integrative breast cancer treatment in women, which, in turn, may improve cancer care as well as quality and quantity of life with cancer. Trial registration German Clinical Trial Register DRKS00014852. Retrospectively registered at July 4th, 2018.

Download Full-text

Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study

BMJ Open ◽

10.1136/bmjopen-2020-042493 ◽

2021 ◽

Vol 11 (2) ◽

pp. e042493

Author(s):

Astrid-Jane Williams ◽

Ramesh Paramsothy ◽

Nan Wu ◽

Simon Ghaly ◽

Steven Leach ◽

...

Keyword(s):

Cohort Study ◽

Environmental Factors ◽

Prospective Cohort Study ◽

Clinical Data ◽

Prospective Cohort ◽

Response To Therapy ◽

Psychological State ◽

Local Health ◽

Microbial Composition ◽

Patient Reported

IntroductionCrohn’s disease and ulcerative colitis are common chronic idiopathic inflammatory bowel diseases (IBD), which cause considerable morbidity. Although the precise mechanisms of disease remain unclear, evidence implicates a strong multidirectional interplay between diet, environmental factors, genetic determinants/immune perturbations and the gut microbiota. IBD can be brought into remission using a number of medications, which act by suppressing the immune response. However, none of the available medications address any of the underlying potential mechanisms. As we understand more about how the microbiota drives inflammation, much interest has focused on identifying microbial signals/triggers in the search for effective therapeutic targets. We describe the establishment of the Australian IBD Microbiota (AIM) Study, Australia’s first longitudinal IBD bioresource, which will identify and correlate longitudinal microbial and metagenomics signals to disease activity as evaluated by validated clinical instruments, patient-reported surveys, as well as biomarkers. The AIM Study will also gather extensive demographic, clinical, lifestyle and dietary data known to influence microbial composition in order to generate a more complete understanding of the interplay between patients with IBD and their microbiota.MethodsThe AIM Study is an Australian multicentre longitudinal prospective cohort study, which will enrol 1000 participants; 500 patients with IBD and 500 healthy controls over a 5-year period. Assessment occurs at 3 monthly intervals over a 24-month period. At each assessment oral and faecal samples are self-collected along with patient-reported outcome measures, with clinical data also collected at baseline, 12 and 24 months. Intestinal tissue will be sampled whenever a colonoscopy is performed. Dietary intake, general health and psychological state will be assessed using validated self-report questionnaires. Samples will undergo metagenomic, transcriptomic, proteomic, metabolomic and culturomic analyses. Omics data will be integrated with clinical data to identify predictive biomarkers of response to therapy, disease behaviour and environmental factors in patients with IBD.Ethics and disseminationEthical approval for this study has been obtained from the South Eastern Sydney Local Health District Research Ethics Committee (HREC 2019/ETH11443). Findings will be reported at national and international gastroenterology meetings and published in peer-reviewed journals.Trial registration numberACTRN12619000911190.

Download Full-text